Bushu Nearing Completion of Its 42,000 Square Foot Cold Chain...

Pharma Tech Outlook: Pharma Tech Magazine

Bushu Nearing Completion of Its 42,000 Square Foot Cold Chain Warehouse Facility

By Pharma Tech Outlook | Friday, August 21, 2020

Koichiro Matsumoto, CEO

The added space and inspection lines will allow Bishu to bring more of its client's bulk products into the country, which will make their logistics and supply chain more efficient.

FREMONT, CA: Bushu Pharmaceuticals, one of Japan's largest contract manufacturers of pharmaceutical products, unveils a major capital program costing $100 million to widen its footprint, capacity and portfolio of services over the coming five years.

Bushu is reaching its 42,000 square foot cold chain warehouse facility at its Misato plant north of Tokyo. The latest facility will be commissioned and validated by September of this year for the storage of temperature-controlled sterile drugs and biologics for the Japanese market. The new facility is a significant component in the company's "Asia hub" strategy, which allows international pharmaceutical companies to import bulk products into Japan for quality inspection, labelling, packaging and distribution throughout APAC.

The inspection potential will be raised to 12 stations for pre-filled syringes, and seven stations each for liquid vials and for lyophilized vials. Of the 26 inspection stations, 23 will be assisted by cameras. This will establish Bushu as a pioneering provider of sterile drug inspection in Japan's outsourced market. The Japanese market requires 100% visual inspection of pharmaceutical products intended for sale in Japan, which is time-consuming and complex for sterile and biologic products.

Besides the new warehouse and inspection capacity, Bushu has funded the addition of eight new packaging lines, including one pre-filled packaging line and a new water-for-injection line to support its sterile manufacturing filling suite. Bushu is upgrading its production automation systems and its laboratory information management system (LIMS) as part of a long-term IT strategy.

Bushu is now working with various multinational pharmaceutical clients, which allows the company to develop an international technology transfer team. This expanded team will facilitate the transfer of analytical methods and allow validation of foreign-made drugs into Bushu's two manufacturing facilities.

To head the organization during this time of expansion, Bushu has also appointed Koichiro Matsumoto as President and CEO of the company as of July 6.

Weekly Brief

Read Also